HAYA Therapeutics has inked a multi-year agreement with Eli Lilly for advancements in drug discovery treatments related to obesity and related metabolic diseases. As part of the agreement, HAYA will receive an upfront payment, including equity investment, and is eligible for up to USD 1 billion in preclinical, clinical, and commercial milestone payments, as well as royalties on product sales.
The agreement includes using HAYA's RNA-guided regulatory genome platform to support preclinical drug discovery, potentially leading to effective and less harmful treatments.
Analyst QuickTake: The agreement between HAYA and Eli Lilly is a part of the latter’s recent plans to expand its scope and product pipeline. In June 2024, Eli Lilly entered an agreement with Radionetics Oncology to establish a path to potentially acquire the company and gain access to its pipeline of cancer radiotherapeutics. Additionally, in the same month, Eli Lilly acquired biopharmaceutical company Morphic Holding to expand its immunology portfolio and develop new therapies in gastroenterology.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.